Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report

12 Feb 2026 07:00 CET

Oslo, Norway, February 12, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”)
today published its interim financial report for the second half of 2025 and
released its fourth quarter 2025 presentation.

The interim report has been prepared in accordance with IAS 34 and includes
financial information for the fourth quarter and the second half of 2025.

Q4 2025 highlights and developments
• Positive interim clinical data from the Phase II NeoLIPA neoadjuvant melanoma
study were presented by Dr Henrik Jespersen at the Nordic Melanoma Meeting in
November 2025. Overall pathological responses was obtained in nearly 90% of
patients treated with ruxotemitide in combination with pembrolizumab.
• Licensing partner Verrica Pharmaceuticals presented new immune-response data
from its ongoing Phase II study with ruxotemitide in basal cell carcinoma at the
Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting.
• The ATLAS-IT-05 Phase II study in advanced melanoma was completed, with
preparation of the clinical study report ongoing and expected to be finalized in
the first quarter of 2026.
• Evaluating all strategic opportunities to accelerate the development of
LTX-401.
• Cash and short-term financial investments totaled NOK 72.4 million at year-end
2025, reflecting disciplined cost management and reduced operating loss
following completion of major clinical activities.


Ruxotemitide is progressing toward commercialization via multiple avenues: our
internal work on neoadjuvant melanoma via the NeoLIPA study and our internal
planning towards a pivotal study; Active partnering conversations to ensure
strategic optionality; and Verica Pharmaceuticals continued efforts to source
non-dilutive funding for a pivotal trial in basal cell carcinoma. These
initiatives offer multiple opportunities to create significant market value in
superficial tumors.

Lytix remains open to valuable partnerships that can speed up development,
maximize the global potential of the program, and ensure patients gain access to
this drug as quickly as possible. With continued financial discipline, Lytix
remains well-positioned for 2026.

Comment from management
“The data presented during the quarter at the Nordic Melanoma Meeting and at the
Society for Immunotherapy of Cancer underscore the consistency and breadth of
ruxotemitide’s immune-mediated activity across disease settings,” said Øystein
Rekdal, CEO of Lytix Biopharma. “Seeing strong pathological responses in
early-stage melanoma alongside immune activation data in basal cell carcinoma is
deeply motivating for the entire team and represents an important milestone as
we advance ruxotemitide toward the next phase of development.”

The Company’s fourth quarter 2025 results and developments will be presented in
a live webcast with CEO Øystein Rekdal and CFO Gjest Breistein today at 10:00
CET.

Webcast details:
Date: Thursday, February 12, 2026
Time: 10:00 CET

Questions may be submitted in advance to: post@lytixbiopharma.com

The presentation and subsequent Q&A session will be conducted in English and can
be viewed live by registering here:
https://qcnl.tv/p/Bs5cUOyZOtu__8Vd3OK5_Q

A recording of the presentation will be made available after the webcast at:
https://www.lytixbiopharma.com/financial-reports

The interim report for the second half of 2025 and the fourth quarter
presentation are available on the Company’s website.

For further information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma’s lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com

More information:
Access the news on Oslo Bors NewsWeb site

665487_2025-H2 - Lytix Biopharma - Interim Report - IFRS - 2025-12-31 - Final.pdf
665487_2025-Q4 - Lytix Biopharma - Quarterly Presentation - 2025-12-31 - Final.pdf